Table 3.
Adverse events, drug use and attrition during 28 day buprenorphine administration in Caucasian, African-American and Hispanic participants
| Race/ Ethnic Group | Caucasian n = 558A |
African- American n = 93B |
Hispanic n = 73C |
p-value |
|---|---|---|---|---|
| Total Adverse Events,Mean # of events ± SD | 5.2 ± 4.0 | 2.9 ± 2.0 | 4.9 ± 3.0 | < 0.001 |
| Adverse Events Definitely Not Study Drug Related, Mean # of events ± SD | 3.7 ± 3.3 | 1.5 ± 1.4 | 3.8 ± 3.0 | < 0.001 |
| Opioid-positive Urine Test at Randomization, n(%) | 144 (36.7%) | 18 (31.0%) | 20 (41.7%) | 0.520 |
| Any Drug-positive Urine Test at Randomization, n(%) | 260 (66.3%) | 37 (63.8%) | 33 (68.8%) | 0.862 |
| Attrition during Buprenorphine administration, n(%) | 165 (29.6%) | 33 (35.5%) | 25 (34.3%) | 0.415 |
| Buprenorphine dose at randomization, mean score ± SD | 20.4 ± 5.2 | 18.8 ± 5.9 | 21.2 ± 5.1 | 0.045 |
A
At randomization, the sample size is reduced to 392 for Urine test, 393 for buprenorphine dose.
B
At Randomization, the sample size is reduced to 58 for Urine test, 60 for buprenorphine dose.
C
At randomization, the sample size is reduced to 48 for Urine test, and buprenorphine dose.